Wang et al. reported that in lenvatinib-resistant HCC cells, the excessive activation of BCL2 interacting protein 3 (BNIP3)-driven mitophagy enhanced glycolytic flux, resulting in constantly sustained competitive edge of lenvatinib-resistant cells over their sensitive counterparts, which maintained LR 63. The gene discussed is BNIP3; the disease is hepatocellular carcinoma.